The University of British Columbia

University of Saskatchewan

Qingdao Primedicine Pharmaceutical Company, Ltd.

Wang, Yu Tian

Taghibiglou, Changiz

Yu Tian Wang

Changiz Taghibiglou

Jack Wuyang Jin

Xuelai Fan

Shu Zhang

Anthony George Phillips

Lidong Liu

Peter Axerio-Cilies

Yitao Liu

Yushan Wang

Wu Yang Jin

Anthony Phillips

In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.

Peptide directed protein knockdown

In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase I and the CMPD is protein transduction domain of the HIV-1 Tat protein.

This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.

N-methyl-d-aspartate receptor allosteric modulators and methods for their use

The present application provides compositions, methods, and uses of polypeptide or antibody inhibitors of insig-1 ubiquitination for preventing or treating skin diseases or conditions associated with overproduction of sebum, such as acne and seborrhea.

Polypeptides and antibodies to treat skin conditions associated with overproduction of sebum

Described herein are isolated polypeptides having phosphatase and tensin homolog (PTEN) inhibitory activity, vectors and cells for the expression thereof and methods for their use in treating diseases associated with cytotoxic stress, such as spinal cord injury, stroke, traumatic brain injury, multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease.

Inhibitors of phosphatase and tensin homolog (PTEN) compositions, uses and methods

Methods and compositions for treating neurological damage or dysfunction are described, including methods implemented by administration of peptide inhibitors of AMPA receptor endocytosis.

Growing community of inventors

Vancouver, Canada

Yu Tian Wang